Table 5.
Antiproliferative Activities of 1–19 (IC50 in μM) in Vitro
| A-549 | MDA-MB-231 | KB | KB-VIN | MCF-7 | |
|---|---|---|---|---|---|
| 1 | 8.6 ± 0.1 | 7.7 ± 0.1 | 7.4 ± 0.3 | 6.6 ± 0.1 | >10 |
| 2 | >10 | >10 | >10 | >10 | >10 |
| 3 | 5.9 ± 0.0 | 8.2 ± 0.1 | 5.7 ± 0.2 | 5.8 ± 0.2 | 8.3 ± 0.3 |
| 4 | 4.3 ± 0.2 | 4.5 ± 0.2 | 4.7 ± 0.0 | 4.8 ± 0.0 | 4.6 ± 0.1 |
| 5 | 4.7 ± 0.0 | 5.1 ± 0.1 | 4.8 ± 0.4 | 4.9 ± 0.3 | 6.0 ± 0.1 |
| 6 | 5.3 ± 0.0 | 4.8 ± 0.0 | 4.8 ± 0.1 | 4.7 ± 0.1 | 5.6 ± 0.2 |
| 7 | 4.3 ± 0.1 | 4.5 ± 0.2 | 4.5 ± 0.2 | 4.9 ± 0.0 | 4.9 ± 0.0 |
| 8 | 9.8 ± 0.0 | 5.2 ± 0.4 | 6.7 ± 0.4 | 8.3 ± 0.4 | >10 |
| 9 | 3.1 ± 4.4 | 2.8 ± 3.9 | 2.7 ± 3.8 | 2.6 ± 3.6 | 3.0 ± 4.3 |
| 10 | 4.5 ± 0.1 | 4.8 ± 0.1 | 4.2 ± 0.2 | 4.1 ± 0.0 | 5.3 ± 0.1 |
| 11 | 4.9 ± 0.0 | 8.2 ± 0.2 | 4.5 ± 0.1 | 4.7 ± 0.2 | 6.5 ± 0.0 |
| 12 | 4.3 ± 0.2 | 4.5 ± 0.0 | 4.3 ± 0.2 | 4.4 ± 0.3 | 4.8 ± 0.0 |
| 13 | 3.5 ± 0.1 | 4.8 ± 0.1 | 4.3 ± 0.1 | 4.7 ± 0.1 | 4.8 ± 0.1 |
| 14 | >10 | >10 | >10 | >10 | >10 |
| 15 | 4.2 ± 0.1 | 4.3 ± 0.1 | 4.1 ± 0.1 | 4.3 ± 0.1 | 4.9 ± 0.1 |
| 16 | 4.4 ± 0.0 | 3.2 ± 0.1 | 4.6 ± 0.1 | 4.4 ± 0.0 | 4.4 ± 0.1 |
| 17 | 5.6 ± 0.1 | 4.8 ± 0.1 | 5.0 ± 0.1 | 5.1 ± 0.0 | 6.1 ± 0.6 |
| 18 | 4.3 ± 0.0 | 4.5 ± 0.1 | 4.8 ± 0.1 | 4.4 ± 0.1 | 4.7 ± 0.3 |
| 19 | 4.4 ± 0.0 | 5.2 ± 0.0 | 5.0 ± 0.2 | 4.1 ± 0.2 | 5.6 ± 0.0 |
| VIN (nM)a | 23.0 ± 2.4 | 32.0 ± 0.5 | 4.4 ± 0.1 | 2480 ± 28.2 | 7.3 ± 0.2 |
| PXL (nM)b | 4.5 ± 0.9 | 7.0 ± 0.9 | 3.6 ± 1.1 | 2360 ± 59.5 | 8.8 ± 1.0 |
a
VIN = vinblastine.
b
PXL = paclitaxel. VIN and PXL were positive controls.